Cancerous neuropathic pain
Conditions
Interventions
Experimental group :Erexib is combined with Mercy Contin and Lerica
Control group :Mercy Contin and Lerica
Sponsors
Jilin Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as malignant tumors with advanced cancerous neuropathic pain; 2. No history of opioid abuse before admission; 3. No history of mental illness, language skills, can accurately express pain; 4. The estimated survival time is greater than 4 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients with nausea and vomiting, indwelling catheterization, and intestinal obstruction before admission; 2. Pregnant and lactating women; 3. Those who are allergic to the drugs in this study; 4. Severe gastrointestinal disease and cardiac insufficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numerical Pain Score (NRS) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The dose of Mercy Contin applied;The occurrence of adverse reactions; | — |
Countries
China
Contacts
Public ContactHou Junjie
Jilin Provincial People's Hospital
Outcome results
None listed